FDA’s Division of Drug Information is presenting a series of continuing education (CE) webinars targeting the needs of all health care professionals.
FDA Drug Topics: Drug Shortages: Root Causes and Potential Solutions
June 28, 2022
Time: 1:00 PM to 2:00 PM (ET)
Register
After registering, you will receive a calendar invitation with details on how to join the online meeting.
An email will be sent to all participants by the next business day with instructions on how to claim CE and a copy of the presentation slides.
Activity Outline
Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. Drug shortages can have serious effects on patients who may experience treatment delays, receive alternative treatments that are not as effective or well-tolerated, or forgo treatment. These outcomes can prolong patient suffering, contribute to disease progression, and result in other adverse health outcomes that reduce patient well-being and increase morbidity. Mitigating and preventing drug shortages is a priority for FDA. This webinar will provide a general overview of CDER’s Drug Shortage program, current shortage issues and challenges.
References:
Explanation of FDA and ASHP shortage posting
FDA Eighth Annual Report on Drug Shortages for Calendar Year 2020
FDA Shortages Additional News And information
Federal Food, Drug, and Cosmetic Act (FD&C Act), Section 506C (21 USC 356c)
Federal Register Final Rule, 80 FR 38915 (July 8, 2015), Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products. See also 21 CFR 310.306, 314.81, and 600.82.
CDER MAPP 4190.1 Rev. 2, Drug Shortage Management (11/1995; Rev. 1, 9/2006; Rev. 2, 9/2014)
Series Objectives:
Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.
Learning Objectives: After completion of this activity, the participant will be able to:
Identify what FDA can and cannot do to prevent and mitigate drug shortages
Describe how to report a drug shortage to the FDA
Summarize pharmaceutical Industry’s role in drug shortage prevention and mitigation
Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students.
Schedule:
1:00 pm – 2:00 pm – FDA Drug Topics: Drug Shortages: Root Causes and Potential Solutions presented by CDR Emily Thakur, RPh, Team Leader, and CDR Hyun Son, PharmD, Senior Program Management Officer, with the Drug Shortage Staff (DSS), Office of the Center Director (OCD), in FDA’s Center for Drug Evaluation and Research (CDER).
Continuing Education Accreditation:
Joint AccreditationIn support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
IPCE CreditThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-22-011-L04-P. and ACPE Universal Activity Number JA0002895-0000-22-011-L04-T for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
PA AAPA Category 1 CMEAAPA
This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.
CPH
Up to 1.00 CPH Recertification Credits may be earned at this event.
Requirements for receiving CE Credit:
Physicians, physician assistants, nurses, pharmacists, pharmacy technicians, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation survey via the CE Portal (ceportal.fda.gov). Final activity evaluations must be completed within two weeks after the activity – no exceptions.
Attention Pharmacists and Pharmacy Technicians: Failure to provide your correct NABP and Date of Birth information, in the required format, may result in the loss of credit for this activity. NABP profile number should be the 6-7 digit profile number assigned by the CPE Monitor and your birth date should be in the MMDD format (e.g. 0721). Do not provide your pharmacy license number. Please click the “My Account” tab and then navigate to “Edit Contact Information” to verify that your information is correct.
Important Note regarding completion of evaluations and receiving credit:
Attendees have 14 days from the last day of the activity to log in, attest to your attendance, and complete the required evaluation survey, to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the activity to obtain their CE credit.
Disclosure:
Faculty:
Thakur, Emily, RPh, Team Leader, FDA/CDER/OCD/DSS – nothing to disclose
Planning Committee:
Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI – nothing to disclose
Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV – nothing to disclose
DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI – nothing to disclose
Kapoor, Rama, MD, Medical Officer, FDA/CDER/OND/OID/DAI – nothing to disclose
Nguyen-Chu, Thanh Tam, PharmD, BCPS, Pharmacist, FDA/CDER/OCOMM/DDI – nothing to disclose
Paraoan, Dianne, MPH, RN, Associate Director for Regulatory Affairs, FDA/CDER/OMP – nothing to disclose
CE Consultation and Accreditation Team:
Littlefield, Jr, Kenneth P., Training Specialist, FDA/CDER/OEP/DLOD – nothing to disclose
Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD – nothing to disclose
Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.
Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov.
To learn more about future dates and registration, please visit: www.fda.gov/DDIWebinars.